On June 10, 2025, Aldeyra Therapeutics held its annual shareholder meeting where shareholders elected three directors, ratified the appointment of an accounting firm for 2025, and approved executive compensation. Approximately 76.2% of shares were represented, showing significant shareholder engagement.